View Older Stories View More Recent Stories

Jan 14, 2020 06:46AM Lilly (LLY) expands insulin affordability options with lower-priced versions of Humalog Mix75/25� KwikPen and Humalog Junior KwikPen
Jan 14, 2020 06:45AM Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®
Jan 10, 2020 06:30AM Lilly (LLY) Announces Agreement to Acquire Dermira (DERM) for $18.75/Share in $1.1 Billion Deal
Jan 10, 2020 06:30AM Lilly Announces Agreement to Acquire Dermira
Dec 19, 2019 06:45AM Lilly Launches Campaign to Increase Awareness of Insulin Cost-Saving Options
Dec 16, 2019 06:46AM Lilly (LLY) to Integrate Dexcom (DXCM) CGM into Personalized Diabetes Management System
Dec 16, 2019 06:45AM Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System
Dec 13, 2019 08:11AM Boehringer Ingelheim, Lilly (LLY) Jardiance phase III exercise ability studies in chronic heart failure misses primary endpoint
Dec 13, 2019 08:00AM Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
Nov 26, 2019 10:17AM Lilly (LLY) Presents 52-Week Head-to-Head Data from TALTZ Versus Humira Trial in Psoriatic Arthritis at ACR
Nov 26, 2019 10:15AM ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of TALTZ® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Nov 26, 2019 10:15AM ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from TALTZ® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
Nov 17, 2019 10:50AM Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Nov 13, 2019 05:08PM Boehringer Ingelheim, Lilly (LLY) announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Nov 13, 2019 05:07PM Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Nov 12, 2019 08:30AM Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
Oct 28, 2019 10:17AM Lilly (LLY) Presents Positive Results for TALTZ in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV Congress
Oct 28, 2019 10:15AM Lilly Presents Positive Results for TALTZ® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congre
Sep 20, 2019 06:47AM Lilly (LLY) Announces CHMP Issued Positive Opinion to Expand Trulicity Label to Include Results from REWIND Cardiovascular Outcomes Trial
Sep 20, 2019 06:45AM CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
Aug 23, 2019 02:58PM Eli Lilly & Co. (LLY), Incyte (INCY) Baricitinib Met Primary Endpoint in BREEZE-AD7 Trial
Aug 23, 2019 02:55PM Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Aug 8, 2019 06:45AM Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia
Jul 24, 2019 11:19PM BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
Jun 26, 2019 06:46AM Lilly's (LLY) AWARD-11 trial studying higher investigational doses of Trulicity demonstrated superiority in A1C reduction in people with type 2 diabetes
Jun 26, 2019 06:45AM Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes
Jun 26, 2019 06:05AM Eli Lilly & Co. (LLY) Reports FDA Approval of Fast Track Designation for Empagliflozin for Treatment of Chronic Heart Failure
Jun 26, 2019 06:00AM U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Jun 10, 2019 09:30PM Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
Jun 10, 2019 01:00PM New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria
Jun 9, 2019 07:30PM Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
Jun 9, 2019 11:30AM Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions
Jun 8, 2019 08:30PM Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®
Jun 4, 2019 07:31AM Lilly (LLY) Announces FDA Accepts NDA for Triple Combination Tablet for Adults with Type 2 Diabetes
Jun 4, 2019 07:30AM U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
May 22, 2019 06:38AM Lilly (LLY) Says Lower-Priced Insulin is Now Available
May 22, 2019 06:30AM Lilly's Lower-Priced Insulin Now Available
Apr 18, 2019 05:06PM Pfizer (PFE). Eli Lilly & Co. (NYSE:LLY) Report Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Apr 18, 2019 05:05PM Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Mar 20, 2019 08:45AM NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology
Mar 4, 2019 06:31AM Lilly (LLY) Announces it Will Introduce Lower-Priced Insulin
Mar 4, 2019 06:30AM Lilly to Introduce Lower-Priced Insulin
Feb 19, 2019 06:51AM Pfizer (PFE) and Lilly (LLY) Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Feb 19, 2019 06:45AM Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Feb 14, 2019 06:42AM Eli Lilly & Co. (LLY), Boehringer Ingelheim Report CAROLINA Cardiovascular Outcome Trial of Tradjenta Met Primary Endpoint of Non-Inferiority Compared with Glimepiride
Feb 14, 2019 06:30AM Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
Feb 4, 2019 06:46AM Eli Lilly & Co. (LLY), Incyte Corporation (INCY) Report Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Feb 4, 2019 06:45AM Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Jan 29, 2019 06:34AM Pfizer (PFE), Lilly (LLY) Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
Jan 29, 2019 06:30AM Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
View More Recent Stories View Older Stories